Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-11T09:07:02.876Z Has data issue: false hasContentIssue false
  • English
  • Français

Adición de sulpirida a la clozapina en pacientes esquizofrénicos resistentes al tratamiento: un estudio preliminar de una serie clínica

Published online by Cambridge University Press:  12 May 2020

R. Shiloh ,
Z. Zemishlany ,
D. Aizenberg  and
A. Weizman
R. Shiloh
Affiliation:
Hospital Psiquiátrico Geha, Petah Tikva y Facultad Sackler de Medicina, Centro de Investigación Médica Felsenstein, Universidad de Tel Aviv, Tel Aviv, Israel
Z. Zemishlany
Affiliation:
Hospital Psiquiátrico Geha, Petah Tikva y Facultad Sackler de Medicina, Centro de Investigación Médica Felsenstein, Universidad de Tel Aviv, Tel Aviv, Israel
D. Aizenberg
Affiliation:
Hospital Psiquiátrico Geha, Petah Tikva y Facultad Sackler de Medicina, Centro de Investigación Médica Felsenstein, Universidad de Tel Aviv, Tel Aviv, Israel
A. Weizman
Affiliation:
Hospital Psiquiátrico Geha, Petah Tikva y Facultad Sackler de Medicina, Centro de Investigación Médica Felsenstein, Universidad de Tel Aviv, Tel Aviv, Israel
Get access

Resumen

Seis pacientes esquizofrénicos crónicos resistentes a los neurolépticos, que respondían parcialmente a la clozapina, recibieron conjuntamente de manera abierta durante 10 semanas 600 mg/día de sulpirida (un antagonista dopaminérgico selectivo del D 2) com o aumento al tratamiento con clozapina (un bloqueador relativamente débil del D 2). Se observó una notable reducción en los síntomas positivos y negativos en cuatro de los seis pacientes.

Keywords

esquizofreniaclozapinasulpiridadopaminaprolactina
Type
Informe clínico
Information
European Psychiatry (Ed. Española) , Volume 4 , Issue 7 , October 1997 , pp. 476 - 479
Copyright
Copyright © European Psychiatric Association 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografia

Andreasen, NC. Scale or the Assessment of Negative Symptoms (SANS). Iowa City: The University of Iowa, 1983.Google Scholar
Andreasen, NC. Scale for the Assessment of Positive Symptoms (SANS). Iowa City: The University of Iowa, 1984.Google Scholar
Casey, DE, Gerlach, J. Sulpiride in tardive diskinesia. Psychopharmacology (Berlin) 1979; 66: 73–7.CrossRefGoogle Scholar
Cassano, GB, Castrogiovanni, P, Conti, L. Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial. Curr Ther Res 1975; 17: 189–201.Google ScholarPubMed
Edwards, JG, Alexander, JR, Alexander, MS, Gordon, A, Zutchi, T. Controlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry 1980; 137: 522–9.CrossRefGoogle ScholarPubMed
Farmer, AE, Blewett, A. Drug Treatment of resistant schizophrenia. Drugs 1993; 45: 374–83.CrossRefGoogle ScholarPubMed
Gudelsky, GA, Nash, JF, Berry, SA. Basic biology of clozapine. Electrophysiological and neuroendocrinological studies. Psychopharmacology (Berlin) 1989; 99: 513–7.CrossRefGoogle ScholarPubMed
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.CrossRefGoogle ScholarPubMed
Hamryd, C, Bjerkenstedt, L, Bjork, K, Gullbers, B, Oxentiema, G, Sedvall, G, Wiesel, FA, Wick, G, Aberg-Wistedt, A. Clinical evaluation of sulpiride in schizoprenic patients - A double-blind comparison with chlorpromazine. Acta Psychiatr Scand 1984; 69 (suppl 311): 730.Google Scholar
Kane, J. Clinical efficacy of clozapine in treatment of refractory schizophrenia: and overview. Br J Psychiatry 1992; 18 (suppl 17): 41–5.CrossRefGoogle Scholar
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment of resistant schizophrenia. Arch Gen Psychiatry 1988; 45: 789–96.CrossRefGoogle Scholar
Lieberman, J, Saltz, B, Johns, C, Pollak, S, Borentein, M, Kane, J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503.CrossRefGoogle ScholarPubMed
Mielke, DH, Gallant, DM, Roniger, JJ, Kessler, C, Kessler, LR. Sulpiride: evaluation of antipsychotic activity in schizophrenic patients. J Nerv Ment Dis 1977; 38: 569–71.Google ScholarPubMed
Moriuchi, K, Imazu, Y, Yoneda, H. Differences in effects of sultopride and sulpiride on dopamine tumover in rat brain. Neurochem Res 1995; 20: 95–9.CrossRefGoogle Scholar
Nishiura, M. Clinico-pharmacological studies of sulpiride. Curr Ther Res 1976; 20: 164–72.Google ScholarPubMed
Niskanen, P, Tamminen, T, Viukari, M. Sulpiride versus amitryptiline in the treatment of depression. Curr Ther Res 1975; 17: 281.Google Scholar
Overall, JE, Gorham, DE. The brief psychiatric rating scale. Psychol Rep 1961; 10: 799–812.CrossRefGoogle Scholar
Pickar, D, Owen, RR, Litman, RE, Hisiao, JK, Su, TP. Predictors of clozapine response in schizophrenia. J Clin Psychiatry 1994; 55: 129–32.Google Scholar
Pucak, ML, Grace, AA. Evidence that systematically administered dopamine antagonists active dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J Pharmacol Exp Ther 1994; 271: 1181–92.Google Scholar
Tamminga, CA, Gerlach, J. New neuroleptics and experimental anti psychotics in schizophrenia.In: Meltzer, HY, ed. Psychopharmacology, the Third Generation of Progress. New York: Raven Press, 1987: 1130–2Google Scholar